Background and objective: Corticosteroids and immunosuppressive agents are considered mainstays of therapy for connective tissue disease-related interstitial lung disease (CTD-ILD); however, tacrolimus with corticosteroid therapy has not been fully investigated. Our objectives were to examine the multidimensional therapeutic benefit and tolerability of the combined therapy for the initial treatment of patients with CTD-ILD. Methods: In this retrospective case series, we identified consecutive CTD-ILD patients treated with tacrolimus plus intravenous (i.v.) methylprednisolone (1000 mg i.v. 3 days a week for 2 weeks) followed by low-dose prednisolone (10 mg/day). We assessed the multidimensional therapeutic benefit and tolerability including lung physiology, exercise capacity, exercise oxygen desaturation, modified Medical Research Council (MMRC) and St George's Respiratory Questionnaire (SGRQ). Results: A total of 26 ILD patients with the underlying CTD diagnoses included 11 with rheumatoid arthritis, 9 with dermatomyositis, 4 with Sjögren's syndrome and 2 others. From baseline to 12 months, the combined therapy significantly improved forced vital capacity (FVC; 77.8% to 94.6%, P < 0.001), diffusing capacity of the lung for carbon monoxide (DL CO ; 66.1% to 75.1%, P < 0.001), 6-min walk distance (6MWD; 530 to 568 m, P = 0.02), lowest oxygen saturation on pulse oximetry (SpO 2 ; 85% to 89%, P = 0.01), MMRC (1.3 to 0.8, P = 0.01) and SGRQ (38 to 21, P < 0.001). During the study period, only one patient's therapy was discontinued due to an adverse event and none had a lifethreatening adverse event attributed to the combined therapy.
INTRODUCTION
Interstitial lung disease (ILD) is one of the most common and clinically important manifestations of connective tissue disease (CTD). 1 In daily practice, corticosteroids and immunosuppressive agents are regarded as the mainstay of therapy for CTD-associated ILD (CTD-ILD). However, the optimal treatment method for CTD-ILD patients remains controversial because there have been only a few controlled studies in systemic sclerosis-related interstitial pneumonia (SSc-IP). 2, 3 Tacrolimus (FK506) is an immunosuppressant that acts as a calcineurin inhibitor and selectively suppresses T-cell activation and IL-2 transcription. 4 It also inhibits the functions of P-glycoprotein, 5 which is reported to be one of the mechanisms of resistance to corticosteroids. 6 It is reported that tacrolimus suppresses collagen synthesis and expression of the transforming growth factor beta 1 (TGF-β1) receptor in lung fibroblasts. 7 Based on these findings, tacrolimus appears to be a promising therapy for CTD-ILD patients. In recent years, several studies such as case reports, small trials and systematic reviews have reported that tacrolimus may be useful in treating polymyositis/dermatomyositis(PM/DM)-associated ILD. [8] [9] [10] However, most previous studies assessed the efficacy of tacrolimus as add-on therapy for refractory interstitial pneumonia; to our knowledge, no study has evaluated the efficacy of tacrolimus as an initial therapy.
Recently, the CTD ILD Working Group of Outcome Measures in Rheumatology has developed consensus criteria for measuring disease activity and therapeutic response in CTD-ILD. 11 Based on this expert consensus, lung physiology, exercise capacity, exercise oxygen desaturation and patient-reported outcomes (PRO) such as dyspnoea and health-related quality of life (HRQoL) have been provisionally proposed as important outcomes for CTD-ILD. 12 However, only a few studies to date have evaluated drug efficacies multidimensionally. In this retrospective study, we reviewed 26 consecutive patients with CTD-ILD to evaluate the multidimensional effects of tacrolimus as an initial therapy.
METHODS

Patient selection
The medical records of patients with CTD-ILD treated with tacrolimus and prednisolone were analysed retrospectively. A total of 26 patients with CTD-ILD were treated with tacrolimus as initial therapy at the Tosei General Hospital (Aichi, Japan) between January 2012 and September 2015. Patients who met the criteria for acute exacerbation of interstitial pneumonia were excluded from this analysis (for details, see Fig. S1 , Supplementary Information). Of the 26 patients, 23 (88%) showed deterioration of lung function and/or radiological findings. Two patients had no previous data and one patient showed deterioration of systemic symptoms. Overall, most patients showed a deterioration of ILD. The decision to initiate treatment was made through multidisciplinary discussion in our hospital based on patients' conditions. The Ethics Committee of Tosei General Hospital approved the study (IRB #586), and determined that the patients' approval or informed consent was not required because the study involved a retrospective review of patient records.
Diagnosis of CTD and ILD
Patients were classified according to the following criteria: rheumatoid arthritis (RA), PM/DM, clinically amyopathic DM (CADM), Sjögren's syndrome (SjS) and SSc. [13] [14] [15] [16] [17] The diagnosis of ILD was determined by review of lung biopsy findings assessed by an expert pulmonary pathologist or high-resolution computed tomography scan (HRCT) assessed by an expert thoracic radiologist. The thoracic radiologist evaluated the usual interstitial pneumonia (UIP) pattern according to the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society/Latin American Thoracic Association 2011 guidelines. 18 
Treatment methods
All patients were treated with tacrolimus plus intravenous (i.v.) methylprednisolone (1000 mg i.v. for 3 days a week for 2 weeks) followed by low-dose prednisolone (10 mg/day).
The initial tacrolimus dose was 0.0375 mg/kg twice a day or 3 mg a day orally (Fig. 1) . The blood level of tacrolimus was monitored monthly to adjust the dose. We attempted to keep the blood trough level of tacrolimus between 5 and 10 ng/mL throughout the duration of treatment. Oral trimethoprim-sulfamethoxazole (TMP-SMX) was used as a prophylactic agent from the start of the 1-year therapy.
Assessment approaches
The response to this therapy of the following variables was analysed at baseline, 1, 6 and 12 months.
Pulmonary function tests
All patients underwent spirometry and diffusing capacity of the lung for carbon monoxide (DL CO ) (both CHESTAC-55V; Chest, Tokyo, Japan), according to the 
ATS/ERS
recommendations, as physiological assessments. 19, 20 Exercise capacity
The 6-min walk test was conducted according to the ATS statement. 21 The distance in metres was recorded. Oxygen saturation was also measured immediately after the test.
Patient-reported outcomes
The modified Medical Research Council (MMRC) scale (score range 0-4, with higher scores indicating greater impairment) was used to assess the degree of dyspnoea. 22 The St George's Respiratory Questionnaire (SGRQ) was used to assess HRQoL. 23 The total SGRQ score ranges from 0 to 100, with higher scores indicating greater disability.
Peripheral muscle strength
Hand grip force (HF) was measured using a hydraulic hand dynamometer (Smedley Dynamometer; TTM, Tokyo, Japan). Percent predicted values of HF were calculated with predictive equations for isometric peripheral muscle strengths. 24 Quadriceps force (QF) was measured using a dynamometer (Cybex II; Lumex, Bay Shore, NY, USA). The peak torque (in Nm) was assessed in both legs during a maximal isokinetic knee extension manoeuvre with the hip in 90 flexion. The peak torque was then normalized by body mass (Nm/kg).
Definition of significant change
Clinically significant improvement/deterioration in lung physiology (composite categorical change) was defined based on previous reports: ≥10% relative increase/decline in forced vital capacity (FVC) or ≥5% to <10% relative increase/decline in FVC and ≥15% relative increase/decline in DL CO . 25 The minimal clinically important difference (MCID) was utilized as the threshold: 28 m improvement/deterioration in 6-min walk distance (6MWD), ≥1 point increase/decrease in MMRC and ≥7 point decrease/increase in total SGRG score. [26] [27] [28] In 6MWD and MMRC, the significant change for idiopathic pulmonary fibrosis (IPF) patients was utilized because of lack of evidence for CTD-ILD.
Monitoring of adverse drug reactions
Clinical and laboratory data were obtained retrospectively from medical records. Laboratory tests were performed twice a week during the induction phase and at least once a month thereafter. Adverse events, blood pressure, renal function and liver enzymes were evaluated at monthly follow-up visits.
Renal dysfunction was defined as an increase in baseline creatinine levels of 30% at any study time point 29 and liver dysfunction was defined as exceeding twice the upper limit of normal based on the Common Terminology Criteria for Adverse Events ver. 4.0.
Statistical analysis
Data are presented as counts or as medians with interquartile ranges (IQR). A linear mixed model with Bonferroni post hoc analysis was used to evaluate repeated measurements of continuous values including lung physiology variables, 6MWD, lowest oxygen saturation on pulse oximetry (SpO 2 ), MMRC, SGRQ and peripheral muscle strength. Statistical analyses were performed using SPSS (Version 24; IBM, Tokyo, Japan).
RESULTS
Baseline patient characteristics and frequency of pathological patterns
The baseline characteristics of the 26 consecutive patients are summarized in Table 1 . On average, mild restrictive lung physiology and mild DL CO reduction were observed at baseline (median FVC: 2.2 L, 79.6% of predicted; median DL CO : 11.1 mL/min/mm Hg, 69.8% of predicted). Before being diagnosed with ILD, four patients had received treatment for CTD: one with prednisolone 5 mg/day, one with prednisolone 5 mg/ day and an antirheumatic drug (salazosulfapyridine) and two with biologic therapy (tocilizumab and abatacept). No patients had received supplemental oxygen.
Among the 26 patients with CTD, 11 had the UIP pattern (6 diagnosed by surgical lung biopsy (SLB) and 5 by the typical UIP pattern on HRCT 18 ), 8 patients had the non-specific interstitial pneumonia (NSIP) pattern (all diagnosed by SLB), 3 patients had the NSIP with organizing pneumonia (OP) pattern (all diagnosed by SLB), 1 patient had the OP pattern (diagnosed by SLB) and the pathological type of the remaining 3 patients was uncertain because SLB was not performed. In other words, 11 had a UIP pattern and 15 had a non-UIP pattern. Diagnosis of ILD pattern was based on HRCT or SLB, with SLB serving as the final diagnosis when discordant.
Treatment efficacy
For the cohort as a whole, the mixed-effects models showed significant improvements in FVC, DL CO , 6MWD, lowest SpO 2 , MMRC, total score of SGRQ, HF and QF at various time points after combined therapy initiation except at 1 month in DL CO , 6MWD, lowest SpO 2 , MMRC and QF (Figs 2-3 and S2 (Supplementary Information)).
Clinically significant categorical improvements after 1 year of therapy in lung physiology, 6MWD, MMRC and SGRQ were observed in 21 of 26 patients (81%), 13 of 24 patients (54%), 13 of 25 patients (52%) and 18 of 25 patients (72%), respectively (Table 2) . Patients with UIP also showed clinically significant categorical improvements in lung physiology (9/11 patients, 82%), 6MWD (5/10 patients, 50%), MMRC (4/9 patients, 44%) and SGRQ (6/10 patients, 60%) (Table 3) . Patients with UIP showed changes from baseline to 12 months in FVC (81.8% to 93.2%, P < 0.001), DL CO (77.1% to 85.5%, P = 0.1), 6MWD (510 to 550 m, P = 0.3), MMRC (1.2 to 0.9, P = 1.0) and SGRQ (38.7 to 25.2, P = 0.005). We provided raw data in Table S1 (Supplementary Information). All but one of the 26 patients did not require further treatment. A DM-NSIP woman received cyclophosphamide as an add-on therapy at 7 months because of progressive disease. The median tacrolimus dose at 1 year was 3 mg (IQR: 3-3 mg) and the median tacrolimus whole blood trough level was 6.3 ng/mL (IQR: 3.9-9.2 ng/mL).
Toxicity during 1 year of therapy
None of the 26 patients had deaths or a life-threatening adverse event attributed to tacrolimus with prednisolone (Table 1) . In our study, five of these patients (19%) showed an increase in their baseline creatinine levels by 30%. Tacrolimus was discontinued in one patient because of severe muscle cramping. This symptom resolved after discontinuation of the drug.
DISCUSSION
This is the first study to assess the initial treatment effect and the tolerability of the combined therapy with tacrolimus and prednisolone for CTD-ILD. One year of this therapy improved not only lung physiology but also exercise capacity and PRO such as dyspnoea and HRQoL. None of the patients had a life-threatening adverse event attributed to the combined therapy. This combined therapy might be feasible and appeared to demonstrate multidimensional effects on CTD-ILD.
The regimen we adopted resulted in significant improvement in lung physiology. Twenty-one patients (81%) showed a clinically significant improvement. 25 Our therapy also resulted in significant improvement in exercise capacity and PRO such as dyspnoea and HRQoL which are involved in a recently proposed core set of outcome measurements in CTD-ILD. 12 Notable in our study is that clinically significant categorical improvements in 6MWD, MMRC and SGRQ were observed in 13 of 24 patients (54%), 13 of 25 patients (52%) and 18 of 25 patients (72%) after 1 year of therapy, respectively. This study is important in that it revealed that a majority of patients showed an improvement above the MCID for multidimensional assessment.
Several pharmacological advantages of tacrolimus may contribute these favourable results. Previous studies showed that combined therapy with cyclosporine and prednisolone displayed a good response for CTD-ILD patients. 30, 31 Although tacrolimus and cyclosporine have similar mechanisms of action, the potency of tacrolimus in inhibiting in vitro T-cell activation and proliferation is up to 100 times greater than that of cyclosporine. 32 In the area of transplantation, tacrolimus has been shown to improve the graft survival of kidney 33 and liver 34 compared with cyclosporine. Tacrolimus also suppresses collagen synthesis and expression of the TGF-β1 receptor in dermal and lung fibroblasts, 7 but the underlying mechanisms are largely unclear. Recently, Staab-Weijnitz et al. reported that FK506-binding protein 10 (FKBP10) was upregulated in bleomycin-induced lung fibrosis and IPF. Furthermore, loss of FKBP10 expression significantly suppressed collagen secretion. 35 They suggested that inhibition of FKBP10 might contribute to the antifibrotic effects of tacrolimus.
In addition to the above-mentioned efficacy of tacrolimus, we considered several other reasons for the remarkable effects. First, during the induction phase we used high-dose i.v. methylprednisolone. As initial high-dose i.v. methylprednisolone therapy tends to be prescribed in severe cases such as acute ILD, cellular NSIP or OP in CTD-ILD, 36 this strategy may have led to early improvement. Second, because the baseline FVC in our cohort was relatively preserved compared with those in the scleroderma Lung Study I 2 and II 3 (79.6% vs 68.1% and 66.5%), early intervention may have had beneficial effects. 37 Whether highdose steroid therapy or early intervention affects therapeutic response will need to be examined in further studies. Although in a previous study immunosuppressant therapies increased the risk of death, hospitalization and exacerbation in IPF patients, 38 this was not found in the present study, where multidimensional improvements were observed even in some UIP patients. Significant treatment effects in CTD-UIP patients could be attributed to pathological differences, such as more germinal centres, more inflammation and smaller numbers of fibroblastic foci when compared with IPF. 39, 40 The patients in the current study experienced few well-known adverse effects of corticosteroids, such as steroid myopathy. A recent retrospective study reported that chronic corticosteroid treatment (mean daily dose was 20.4 mg/day) contributes to muscle weakness in ILD patients. 41 On the other hand, it was notable that HF and QF were rather improved after 1 year compared with baseline in our study. The use of low-dose corticosteroid in the maintenance phase may contribute to reduced muscle weakness. Furthermore, the improvement of CTD-related symptoms such as joint pain and myopathy may also contribute to the improvements of these factors. The other toxicities observed in this study were mostly mild to moderate and were manageable. Five of these patients (19%) showed an increase in their baseline creatinine levels of 30%, which is similar to a previous systematic review of PM/DM (11.6%). 42 However, no patients had treatment discontinued due to nephrotoxicity. Almost all patients (96%) were able to continue treatment. We speculate that the reasons for the excellent feasibility for 1 year are as follows. First, the patients received low-dose corticosteroid therapy in the maintenance phase. Second, we closely monitored the level of tacrolimus in the blood to adjust the dose of tacrolimus. Third, all patients were prescribed TMP-SMX as prophylactic treatment.
We are aware of the limitations of this work. First, this is a retrospective study from a single institution, and the sample size was small. However, there is little missing data in our study. Second, we could not examine the therapeutic efficacy in each CTD due to the small sample size. Because the treatment effect may vary in each disease due to the heterogeneity of CTD-ILD, further prospective studies need to be done to determine whether a difference exists between individual CTD. Third, a majority of our cohort consisted of patients referred with idiopathic ILD and diagnosed with CTD-ILD after initial evaluation. Therefore, the cohort may differ from the general CTD-ILD population and may be biased. Last, all the patients in the present study were Japanese and it is unclear whether the findings will apply to individuals of different ethnicities. Further comparative studies involving a larger cohort of patients are needed to confirm our results. It is also necessary to analyse the long-term outcome and mortality.
In conclusion, we evaluated the therapeutic benefit and the tolerability of the combined therapy with tacrolimus and prednisolone for CTD-ILD patients. One year of this combined therapy improved not only pulmonary function but also exercise capacity, dyspnoea and HRQoL. The combined therapy appeared to be well tolerated and have a multidimensional effect in this cohort. Further prospective studies will need to be done to determine the effectiveness of this approach in CTD-ILD. This will require a randomized controlled trial specifically comparing the efficacy of tacrolimus Data are shown as number of patients who showed a significant improvement or deterioration/total patients. Significant improvement/deterioration in lung physiology (composite categorical change) was defined as follows: ≥10% relative increase/decline in FVC or ≥5-<10% relative increase/decline in FVC and ≥15% relative increase/decline in DL CO . The MCID was utilized as the threshold: ≥24 m improvement/deterioration in 6MWD, ≥7 points decrease/increase in total score of SGRQ and 1 point decrease/increase in MMRC. One patient who received cyclophosphamide as an add-on therapy was included in the deteriorated patients.
6MWD, 6-min walk distance; DL CO , diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; MCID, minimal clinically important difference; MMRC, modified Medical Research Council; SGRQ, St George's Respiratory Questionnaire; UIP, usual interstitial pneumonia.
versus other traditional therapies such as azatioprine and mycophenolate.
